What is it about?
Shows that differential individual response to treatment is difficult to identify in convential clinical trials
Featured Image
Why is it important?
We do not know how much of the variation in response that we see from patient to patient in clinical trials is genetic, because we rarely design the sorts of trials that would allow us to identify patient-by-treatment interaction.
Read the Original
This page is a summary of: Individual Therapy: New Dawn or False Dawn?, Drug Information Journal, October 2001, Springer Science + Business Media,
DOI: 10.1177/009286150103500443.
You can read the full text:
Resources
Contributors
The following have contributed to this page
